Area of research
Immunology · Surgery
Research interest
Research interests include Atherosclerosis and Cardiovascular Diseases, Lipoproteins and Cardiovascular Health, Antioxidant Activity and Oxidative Stress, and Diabetes, Cardiovascular Risks, and Lipoproteins.
Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA
Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome
Brief communication: Strong concordance of the North American Familial Chylomicronemia Syndrome Score with a positive genetic diagnosis in patients from the Balance study
Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome
Oxidized phospholipids in cardiovascular disease.
Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia
Time-Restricted Feeding Reduces Atherosclerosis in LDLR KO Mice but Not in ApoE Knockout Mice
Time-Restricted Feeding Reduces Atherosclerosis in LDLR KO Mice but Not in ApoE Knockout Mice.
Oxidized phospholipids in cardiovascular disease
APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia
APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia
Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial
Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial
Apolipoprotein C3 induces inflammasome activation only in its delipidated form
High immunoglobulin-M levels to oxidation-specific epitopes are associated with lower risk of acute myocardial infarction
High immunoglobulin-M levels to oxidation-specific epitopes are associated with lower risk of acute myocardial infarction
Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol
Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study
Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study
Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia
Shared Mechanisms between Cardiovascular Disease and NAFLD
Development and validation of an isoform-independent monoclonal antibody–based ELISA for measurement of lipoprotein(a)
The TBK1/IKKε inhibitor amlexanox improves dyslipidemia and prevents atherosclerosis
Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors
Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk
Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements
Oxidized Phospholipids Promote NETosis and Arterial Thrombosis in LNK(SH2B3) Deficiency.
Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease